137 related articles for article (PubMed ID: 37215448)
1. Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.
Badawi M; Menon R; Place AE; Palenski T; Sunkersett G; Arrendale R; Deng R; Federico SM; Cooper TM; Salem AH
J Cancer; 2023; 14(7):1151-1156. PubMed ID: 37215448
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.
Zhang X; Chen J; Wang W; Li X; Tan Y; Zhang X; Qian W
Front Oncol; 2021; 11():693670. PubMed ID: 34290987
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
Condorelli A; Matteo C; Leotta S; Schininà G; Sciortino R; Piccolo GM; Parrinello NL; Proietto M; Camuglia MG; Zucchetti M; Milone G; Di Raimondo F
Cancer Chemother Pharmacol; 2022 Feb; 89(2):267-270. PubMed ID: 34590164
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors.
Büsker S; Jäger W; Poschner S; Mayr L; Al Jalali V; Gojo J; Azizi AA; Ullah S; Bilal M; El Tabei L; Fuhr U; Peyrl A
Cancer Chemother Pharmacol; 2022 May; 89(5):617-627. PubMed ID: 35355137
[TBL] [Abstract][Full Text] [Related]
5. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Place AE; Goldsmith K; Bourquin JP; Loh ML; Gore L; Morgenstern DA; Sanzgiri Y; Hoffman D; Zhou Y; Ross JA; Prine B; Shebley M; McNamee M; Farazi T; Kim SY; Verdugo M; Lash-Fleming L; Zwaan CM; Vormoor J
Future Oncol; 2018 Sep; 14(21):2115-2129. PubMed ID: 29595064
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.
Karbhari N; Lara-Martinez H; Hill JM
Case Rep Oncol; 2022; 15(1):345-350. PubMed ID: 35529288
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.
Kellie SJ; Barbaric D; Koopmans P; Earl J; Carr DJ; de Graaf SS
Cancer; 2002 Mar; 94(6):1815-20. PubMed ID: 11920545
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
9. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections.
Luque S; Grau S; Alvarez-Lerma F; Ferrández O; Campillo N; Horcajada JP; Basas M; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Nov; 44(5):409-15. PubMed ID: 25216547
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.
Glantz MJ; Choy H; Kearns CM; Mills PC; Wahlberg LU; Zuhowski EG; Calabresi P; Egorin MJ
J Natl Cancer Inst; 1995 Jul; 87(14):1077-81. PubMed ID: 7616600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
13. Regional Differences in Penetration of the Protein Stabilizer Trimethoprim (TMP) in the Rat Central Nervous System.
Ineichen BV; Di Palma S; Laczko E; Liddelow SA; Neumann S; Schwab ME; Mosberger AC
Front Mol Neurosci; 2020; 13():167. PubMed ID: 33013318
[TBL] [Abstract][Full Text] [Related]
14. Glymphatic system dysfunction in pediatric acute lymphoblastic leukemia without clinically diagnosed central nervous system infiltration: a novel DTI-ALPS method.
Lin LP; Su S; Hou W; Huang L; Zhou Q; Zou M; Qian L; Cui W; Yang Z; Tang Y; Chen Y
Eur Radiol; 2023 May; 33(5):3726-3734. PubMed ID: 36882529
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
16. Proportion and Pattern of Central Nervous System Involvement in Acute Leukemia on Diagnosis.
Yeasmin S; Rashid MH; Debnath MR; Rashid MM
Mymensingh Med J; 2022 Jan; 31(1):55-60. PubMed ID: 34999680
[TBL] [Abstract][Full Text] [Related]
17. The relationship between cerebrospinal fluid osteopontin level and central nervous system involvement in childhood acute leukemia.
Incesoy-Özdemir S; Sahin G; Bozkurt C; Oren AC; Balkaya E; Ertem U
Turk J Pediatr; 2013; 55(1):42-9. PubMed ID: 23692831
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis.
Müller HL; Oh Y; Gargosky SE; Lehrnbecher T; Hintz RL; Rosenfeld RG
J Clin Endocrinol Metab; 1993 Nov; 77(5):1113-9. PubMed ID: 7521338
[TBL] [Abstract][Full Text] [Related]
19. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia.
Sciumè M; Bosi A; Canzi M; Ceparano G; Serpenti F; De Roberto P; Fabris S; Tagliaferri E; Cavallaro F; Onida F; Fracchiolla NS
Front Oncol; 2023; 13():1149298. PubMed ID: 37051529
[TBL] [Abstract][Full Text] [Related]
20. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
